References:
- Schiopu SRI, Käsmann L, Schönermarck U, Fischereder M, Grabmaier U,
Manapov F, Rauch J, Orban M. Pembrolizumab-induced myocarditis in a
patient with malignant mesothelioma: plasma exchange as a successful
emerging therapy-case report. Transl Lung Cancer Res. 2021
Feb;10(2):1039-1046. doi: 10.21037/tlcr-20-1095. Erratum in: Transl
Lung Cancer Res. 2021 Jun;10(6):3029. PMID: 33718042; PMCID:
PMC7947381.
- Simonaggio A, Michot JM, Voisin AL, et al. Evaluation of
readministration of immune checkpoint inhibitors after immune-related
adverse events in patients with cancer. JAMA Oncol 2019; 5(9):
1310–1317.
- Ganatra S and Neilan TG. Immune checkpoint inhibitorassociated
myocarditis. Oncologist 2018; 23: 879–886.
- Cho JH. Immunotherapy for non-small-cell lung cancer: Current status
and future obstacles. Immune Netw 2017. 17(6):378–391.
doi:10.4110/in.2017.17.6.378
- Farkona S, Diamandis EP, Blasutig IM. Cancer immunotherapy: The
beginning of the end of cancer? BMC Med 2016. 14:73.
doi:10.1186/s12916-016-0623-5.
- Anquetil C, Salem JE, Lebrun-Vignes B, et al. Immune checkpoint
inhibitor–associated myositis: Expanding the spectrum of cardiac
complications of the immunotherapy revolution. Circulation. 2018.
138:743–745. doi:10.1161/CIRCULATIONAHA.118.035898.
- Nishimura H, Okazaki T, Tanaka Y, et al. Autoimmune dilated
cardiomyopathy in PD-1 receptor-deficient mice. Science. 2001.
291(5502):319–22. doi:10.1126/science.291.5502.319.
- Zhang L, Jones-O’Connor M, Awadalla M, et al. Cardiotoxicity of Immune
Checkpoint Inhibitors. Curr Treat Options Cardiovasc Med 2019.
21(7):32. doi:10.1007/s11936-019-0731-6.
- Weber JS, Dummer R, De Pril V, Lebbé C, Hodi FS. Patterns of onset and
resolution of immune-related adverse events of special interest with
ipilimumab: Detailed safety analysis from a phase 3 trial in patients
with advanced melanoma. Cancer. 2013. 119(9): 1675–82.
doi:10.1002/cncr.27969.
- Mahmood SS, Fradley MG, Cohen JV., et al. Myocarditis in Patients
Treated With Immune Checkpoint Inhibitors. J Am Coll Cardiol2018. 71(16):1755–1764. doi: 10.1016/j.jacc.2018.02.037/.